Icon (NASDAQ:ICLR) Releases FY 2026 Earnings Guidance

Icon (NASDAQ:ICLR) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 10.000-11.000 for the period, compared to the consensus earnings per share estimate of 10.380. The company issued revenue guidance of $7.9 billion-$8.2 billion, compared to the consensus revenue estimate of $8.0 billion.

Icon Stock Up 2.4%

ICLR stock opened at $172.08 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.14 and a quick ratio of 1.14. The company’s 50 day simple moving average is $144.41 and its 200-day simple moving average is $136.87. Icon has a 12 month low of $66.57 and a 12 month high of $211.00. The firm has a market capitalization of $13.18 billion, a PE ratio of 30.62, a P/E/G ratio of 8.24 and a beta of 1.22.

Icon (NASDAQ:ICLR) last issued its quarterly earnings data on Tuesday, June 23rd. The medical research company reported $2.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.07. Icon had a return on equity of 8.73% and a net margin of 5.35%.The firm had revenue of $2.03 billion during the quarter, compared to the consensus estimate of $1.98 billion. During the same period in the previous year, the firm posted $3.43 EPS. The company’s quarterly revenue was up 2.5% compared to the same quarter last year. Equities analysts expect that Icon will post 9.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on ICLR shares. UBS Group set a $160.00 price objective on Icon in a research report on Wednesday, June 24th. Piper Sandler cut Icon to a “neutral” rating in a research report on Thursday, May 28th. Leerink Partners set a $145.00 target price on shares of Icon in a research note on Thursday, May 28th. Mizuho upped their target price on shares of Icon from $180.00 to $190.00 and gave the company an “outperform” rating in a report on Friday, June 26th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Icon from $130.00 to $155.00 and gave the stock a “neutral” rating in a report on Thursday, June 25th. Nine investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Icon presently has a consensus rating of “Hold” and an average target price of $173.19.

Hedge Funds Weigh In On Icon

Several institutional investors have recently added to or reduced their stakes in ICLR. Wellington Management Group LLP boosted its stake in Icon by 26.6% in the 3rd quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock worth $811,499,000 after buying an additional 975,268 shares during the last quarter. Orbis Allan Gray Ltd increased its stake in shares of Icon by 1.8% during the 4th quarter. Orbis Allan Gray Ltd now owns 4,214,661 shares of the medical research company’s stock valued at $767,996,000 after acquiring an additional 75,843 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Icon by 9.6% during the 4th quarter. Invesco Ltd. now owns 3,756,896 shares of the medical research company’s stock worth $684,582,000 after acquiring an additional 329,266 shares during the period. Harris Associates L P lifted its holdings in shares of Icon by 7.2% during the 4th quarter. Harris Associates L P now owns 2,510,166 shares of the medical research company’s stock worth $457,402,000 after acquiring an additional 167,607 shares during the period. Finally, Ruane Cunniff & Goldfarb L.P. boosted its position in shares of Icon by 36.2% in the second quarter. Ruane Cunniff & Goldfarb L.P. now owns 1,708,183 shares of the medical research company’s stock worth $248,455,000 after acquiring an additional 453,833 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.